Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (2)
  • children (2)
  • female (1)
  • GMTs (2)
  • humans (1)
  • infant (6)
  • mothers (1)
  • opsonin proteins (2)
  • phagocytosis (1)
  • vaccines (2)
  • Sizes of these terms reflect their relevance to your search.

    The immunogenicity of pneumococcal conjugate vaccine (PCV) has not been evaluated in HIV-infected infants following the first and second PCV-doses. We studied antibody kinetics of serotypes included in 7-valent PCV in HIV-infected and HIV-uninfected infants prior to and following each of three PCV-doses. HIV-uninfected infants born to HIV-uninfected (HUU) and HIV-infected mothers (HEU); and perinatal HIV-infected children with CD(4+)<25% randomized to initiate antiretroviral treatment (ART) when clinically and/or immunologically indicated (ART-) or immediately (ART+) were enrolled. Vaccination occurred at approximately 7.4, 11.5 and 15.5 weeks of age. Serotype-specific antibody was measured by ELISA following each PCV-dose and opsonophagocytic activity (OPA) to three serotypes following the second and third doses. Pre-vaccination, antibody geometric mean concentrations (GMCs) were higher in HUU compared to HIV-exposed groups for most serotypes. GMCs and proportion of infants with antibody ≥0.35 μg/ml were similar in HUU compared to other groups following the second PCV-dose. In all groups, GMCs were greater following the third compared to post-second dose; and a higher proportion within each group had antibody ≥0.35 μg/ml to 6B and 23F. OPA GMTs increased after the third compared to post-second dose for studied-serotypes; as did the proportion with OPA ≥8 to 23F. A two-dose primary-series of PCV probably confers similar protection against invasive pneumococcal disease in HIV-infected compared to HUU children. The inferior response to serotypes 6B and 23F, and lower GMCs and OPA GMTs, following two compared to after three PCV-doses may have implications in the prevention of pneumococcal disease in high-burden countries. Copyright © 2012 Elsevier Ltd. All rights reserved.


    Shabir A Madhi, Alane Izu, Avye Violari, Mark F Cotton, Ravindre Panchia, Els Dobbels, Poonam Sewraj, Nadia van Niekerk, Patrick Jean-Philippe, Peter V Adrian, CIPRA-4 team. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21;31(5):777-83

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 23228814

    View Full Text